Certain male baldness pattern associated with increased risk of aggressive prostate cancer
the ONA take:
According to a new study published online ahead of print in the Journal of Clinical Oncology, frontal plus moderate vertex baldness in men at age 45 is linked with an elevated risk for developing aggressive prostate cancer.
In the study, researchers analyzed data from 39,070 men who participated in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. In order to be included, patients had to have no prior cancer diagnoses, excluding nonmelanoma skin cancer, and be able to recall their hair-loss patterns at age 45 using a modified Norwood-Hamiton scale.
The researchers identified 1,138 cases of prostate cancer, 571 of which were aggressive, during a median follow-up of 2.78 years. Patients with frontal plus moderate vertex baldness at age 45 was not significantly linked with overall prostate cancer risk or nonaggressive prostate cancer risk compared with men with no baldness. By contrast, the same type of baldness was significantly associated with a 40% increased risk for developing aggressive prostate cancer. Other types of baldness were not associated with an increased risk of prostate cancer.
Baldness in men at age 45 is linked with an elevated risk for developing aggressive prostate cancer.
Increasingly, evidence is suggesting that both prostate cancer and male pattern baldness are linked to increased levels of androgens (male sex hormones) and androgen receptors.
In 2013, Medical News Today reported on a study from researchers at the University of Pennsylvania in Philadelphia, who found that African-American men who experience baldness were 69% more likely to develop prostate cancer than those with no baldness.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|